Alkem Labs shareholders approve Adroit Biomed amalgamation with 99.99% votes

Scheme filed with the NCLTStrategic Transactions View source PDF Explain this filing

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.9%Reaction day

₹5374.00

prior close

₹5374.00

announcement price

After-mkt

timing

Nifty Midcap 150market-0.4%+2.3% vs market

Pharmaceuticals peers, median of 175sector+0.0%+1.9% vs sector

On the reaction day the stock moved 2.3 pts more than Nifty Midcap 150 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.2

10m

+1.0

15m

+1.6

30m

+1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.9-0.4+2.3+0.0+1.9

Next day

+0.2-0.6+0.8-0.6+0.7

+0.5-0.3+0.8-0.2+0.7

+0.5-0.2+0.7-0.2+0.7

-0.4-0.1-0.3-0.4-0.0

-0.5+0.3-0.8-0.7+0.3

-0.5+0.2-0.8-0.6+0.1

15d

-3.6-1.6-2.0+1.7-5.3

-0.3-2.4+2.0+1.8-2.1

-6.9-8.3+1.5-3.9-3.0

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 175Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alkem Laboratories held its NCLT-convened equity shareholders meeting on August 17, 2026 to approve the scheme of amalgamation with Adroit Biomed Limited. Shareholders voted overwhelmingly in favor at 99.9999%, with over 99.98 million valid votes polled on total outstanding shares. The special resolution was passed with the requisite majority under Sections 230-232 of the Companies Act, 2013. The scheme now moves toward NCLT sanction and other regulatory approvals before becoming effective.

Likely market impact

Shareholders have approved Adroit Biomed's merger into Alkem. The deal now moves toward NCLT sanction and other regulatory clearances before taking effect.